: Vanta Bioscience Limited Monday said its step-down subsidiary Vayam Research Solutions has entered into an agreement with Pune-based Emcure Pharmaceuticals Ltd to provide bio-analytical and bio-equivalence service for three years from now.
Managing director of Vanta Bioscience Ltd Dopesh Raja Mulakala, in a press release, said the company has state-of-the-art facility and world-class expertise to offer service on global standards.
''We're confident of delivering impeccable results and add continuously value to their business,'' the release quoted Mulakala saying.
An official of Emcure Pharmaceuticals Ltd said efficiency in service, confidentiality and belief in team in-charge of execution were the important factors for selecting the service providers for carrying out bio-analytical and bio-equivalence studies.
''We believe that Vayam has the capabilities,'' he was quoted as saying in a press release.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
